The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib

References

• Soft tissue sarcoma statistics, Cancer Research UK. 2010 [cited 2019 Jun 2]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/soft-tissue-sarcoma
   Google Scholar
• Bone and Soft Tissue Sarcoma UK incidence and survival: 1996 to 2010 version 2.0. National Cancer Intelligence Network, 2013 [cited 2019 Jun 2]. Available at: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/sarcomas/
   Google Scholar
• Linch M, Miah AB, Thway K, et al. Systemic treatment of soft-tissue sarcoma – gold standard and novel therapies. Nat Rev Clin Oncol. 2014;11:187–202.
   PubMed Web of Science ®Google Scholar
• Schaefer IM, Cote GM, Hornick JL. Contemporary sarcoma diagnosis, genetics, and genomics. J Clin Oncol. 2018;36:101–110.
   PubMed Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36:422–439.
   PubMed Web of Science ®Google Scholar
• Wozniak A, Gebreyohannes YK, Debiec-Rychter M, et al. New targets and therapies for gastrointestinal stromal tumors. Expert Rev Anticancer Ther. 2017;17:1117–1129.
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878.
   PubMed Web of Science ®Google Scholar
• Judson I, Bulusu R, Seddon B, et al. UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). Clin Sarcoma Res. 2017;7:6.
   PubMed Web of Science ®Google Scholar
• Phase 3 study of DCC-2618 vs placebo in advanced GIST patients who have been treated with prior anticancer therapies, deciphera pharmaceuticals LLC. 2019 [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03353753
   Google Scholar
• (VOYAGER) Study of avapritinib vs regorafenib in patients with locally advanced unresectable or metastatic GIST, blueprint medicines corporation. 2019 [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03465722
   Google Scholar
• Glod J, Arnaldez FI, Wiener L, et al. A phase II trial of vandetanib in children and adults with succinate dehydrogenase-deficient gastrointestinal stromal tumour. Clin Cancer Res. 2019;25:6302–6308.
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST. Nature. 2019 Oct. doi: 10.1038/s41586-019-1668-3. [Epub ahead of print].
   Web of Science ®Google Scholar
• Van Der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886.
   PubMed Web of Science ®Google Scholar
• Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;4:16.
   PubMed Web of Science ®Google Scholar
• Chamberlain FE, Wilding C, Jones RL, et al. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019;28:505–511.
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–1051.
   PubMed Web of Science ®Google Scholar
• Zopf D, Fichtner I, Bhargava A, et al. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 2016;5:3176–3185.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
   PubMed Web of Science ®Google Scholar
• Patwardhan PP, Ivy KS, Musi E, et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget. 2016;7:4093–4109.
   PubMedGoogle Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207–1219.
   PubMed Web of Science ®Google Scholar
• Dumas J, Boyer S, Riedl B, et al. Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. 2005;WO2005009961A2.
   Google Scholar
• Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116–1119.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–4400.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009;52:4466–4480.
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–7283.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135:1487–1496.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337.
   PubMed Web of Science ®Google Scholar
• Gomez-Rivera F, Santillan-Gomez AA, Younes MN, et al. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signalling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res. 2007;13:4519–4527.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
   PubMed Web of Science ®Google Scholar
• Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, et al. Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. PLoS One. 2015;10:e0142612.
   PubMed Web of Science ®Google Scholar
• Rössler J, Monnet Y, Farace F, et al. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer. 2011;128:2748–2758.
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.
   PubMed Web of Science ®Google Scholar
• Zhang L, Smith KM, Chong AL, et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia. 2009;11:426–435.
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–766.
   PubMed Web of Science ®Google Scholar
• Yin JJ, Zhang L, Munasinghe J, et al. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 2010;70:8662–8673.
   PubMed Web of Science ®Google Scholar
• Najy AJ, Jung YS, Won JJ, et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate. 2012;72:1328–1338.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104.
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67:4408–4417.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661–1672.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691–3698.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932.
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–5058.
   PubMed Web of Science ®Google Scholar
• Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947–4952.
   PubMed Web of Science ®Google Scholar
• Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010;36:492–500.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108:286–291.
   PubMed Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–747.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469–1472.
   PubMed Web of Science ®Google Scholar
• Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–187.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5:1049–1057.
   PubMed Web of Science ®Google Scholar
• Thomison J, McCarter M, McClain D, et al. Hyalinized collage in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol. 2008;35:1003–1006.
   PubMed Web of Science ®Google Scholar
• Vassos N, Agaimy A, Schlabakowski A, et al. An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy. Virchows Arch. 2011;458:363–369.
   PubMed Web of Science ®Google Scholar
• Yanagisawa R, Noguchi M, Fujita K, et al. Preoperative treatment with pazopanib in a case of chemotherapy-resistant infantile fibrosarcoma. Pediatr Blood Cancer. 2016;63:348–351.
   PubMed Web of Science ®Google Scholar
• Robert G, Gabbay G, Bram R, et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009;55:1477–1480.
   PubMed Web of Science ®Google Scholar
• Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102:692–696.
   PubMed Web of Science ®Google Scholar
• Kermiche-Rahali S, Di Fiore A, Drieux F, et al. Complete pathological regression of hepatocellular carcinoma with potal vein thrombosis treated with sorafenib. World J Surg Oncol. 2013;11:171.
   PubMed Web of Science ®Google Scholar
• Ohishi J, Aoki M, Nabeshima K, et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β. BMC Cancer. 2013;13:224.
   PubMed Web of Science ®Google Scholar
• Aoki M, Nabeshima K, Koga K, et al. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest. 2007;87:767–779.
   PubMed Web of Science ®Google Scholar
• Greco A, Roccato E, Miranda C, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A/PDGFB rearrangement. Int J Cancer. 2001;92:354–360.
   PubMed Web of Science ®Google Scholar
• Sjöblom T, Shimizu A, O’Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61:5778–5783.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 2015;14:2452–2462.
   PubMed Web of Science ®Google Scholar
• Wong JP, Todd JR, Finetti MA, et al. Dual targeting of PDGFRα and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors. Cell Rep. 2016;17:1265–1275.
   PubMed Web of Science ®Google Scholar
• Koos B, Jeibmann A, Lünenbürger H, et al. The tyrosine kinase c-Abl promotes proliferation and is expressed in atypicaly teratoid and malignant rhabdoid tumors. Cancer. 2010;116:5075–5081.
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148–3153.
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicentre sarcoma alliance for research through collaborations (SARC) trial. Clin Cancer Res. 2010;16:4884–4891.
   PubMed Web of Science ®Google Scholar
• Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22:452–457.
   PubMed Web of Science ®Google Scholar
• Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60–67.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–1779.
   PubMed Web of Science ®Google Scholar
• Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol. 2018;18:328–336.
   Google Scholar
• Stacchiotti S, Tortoreto M, Baldi GG, et al. Preclinical and clinical evidence of activity of pazopanib in soft fibrous tumour. Eur J Cancer. 2014;50:3021–3028.
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154–3160.
   PubMed Web of Science ®Google Scholar
• Jo JC, Hong YS, Kim KP, et al. A prospective multicentre phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs. 2014;32:369–376.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–1690.
   PubMed Web of Science ®Google Scholar
• Jagodzińska-Mucha P, Świtaj T, Kozak K, et al. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. Tumori. 2017;103:231–235.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23:3171–3179.
   PubMed Web of Science ®Google Scholar
• Khalifa J, Ouali M, Chaltiel L, et al. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 2015;15:700.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Pantaleo MA, Astolfi A, et al. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. Eur J Cancer. 2014;50:1657–1664.
   PubMed Web of Science ®Google Scholar
• Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma a clinico-pathologic study of half a century. Cancer. 1989;63:1–13.
   PubMed Web of Science ®Google Scholar
• Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma. Cancer. 2008;113:3364–3371.
   PubMed Web of Science ®Google Scholar
• Cranshaw IM, Gikas PD, Fisher C, et al. Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol. 2009;35:994–998.
   PubMed Web of Science ®Google Scholar
• Braggio D, Koller D, Jin F, et al. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors. Cancer. 2019;125:2693–2703.
   PubMedGoogle Scholar
• Rosenberg L, Yoon CH, Sharma G, et al. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. Carcinogenesis. 2018;39:681–688.
   PubMed Web of Science ®Google Scholar
• Abraham J, Chua YX, Glover JM, et al. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun. 2012;426:363–368.
   PubMed Web of Science ®Google Scholar
• Maruwge W, D’Arcy P, Folin A, et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signalling. Onco Targets Ther. 2008;1:67–78.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signalling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 2008;7:890–896.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260–266.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology. 2015;89:205–214.
   PubMed Web of Science ®Google Scholar
• Valentin T, Fournier C, Penel N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GS/GETO). Invest New Drugs. 2013;31:1626–1627.
   PubMed Web of Science ®Google Scholar
• Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group. Cancer. 2013;119:2639–2644.
   PubMed Web of Science ®Google Scholar
• Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J. 1998;12:89–96.
   PubMed Web of Science ®Google Scholar
• Yousaf N, Maruzzo M, Judson I, et al. Systemic treatment options for epithelioid haemangioendothelioma: the royal marsden hospital experience. Anticancer Res. 2015;35:473–480.
   PubMed Web of Science ®Google Scholar
• Penel N, Ray-Coquard I, Bal-Mahieu C, et al. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol. 2014;9:273–277.
   PubMed Web of Science ®Google Scholar
• Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082–4090.
   PubMed Web of Science ®Google Scholar
• Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Eng J Med. 2018;379:2417–2428.
   PubMed Web of Science ®Google Scholar
• Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94:1057–1068.
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:1732–1742.
   PubMed Web of Science ®Google Scholar
• Kerr LT, Donoghue JF, Wilding AL, et al. Axitinib has antiangiogenic and antitumorigenic activity in myxoid liposarcoma. Sarcoma. 2016;3484673. doi: 10.1155/2016/3484673 [Epub]
   PubMedGoogle Scholar
• Stacchiotti S, Simeone N, Lo Vullo S, et al. Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study. Eur J Cancer. 2019;106:225–233.
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:581–587.
   PubMed Web of Science ®Google Scholar
• Morton CL, Maris JM, Keir ST, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;58:566–571.
   PubMed Web of Science ®Google Scholar
• Judson I, Scurr M, Gardner K, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or Soft-Tissue Sarcoma. Clin Cancer Res. 2014;20:3603–3612.
   PubMed Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signalling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045–3054.
   PubMed Web of Science ®Google Scholar
• Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013;31:2296–2302.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang Y. Treatment and prognosis of stage IV alveolar soft part sarcoma. Zhonghua Zhong Liu Za Zhi. 2012;34:932–936.
   PubMedGoogle Scholar
• Ogose A, Yazawa Y, Ueda T, et al. Alveolar Soft Part Sarcoma in Japan: multi-Institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology. 2003;65:7–13.
   PubMed Web of Science ®Google Scholar
• Portera CA Jr., Ho V, Patel SR, et al. Alveolar soft part sarcoma. Cancer. 2001;91:585–591.
   PubMed Web of Science ®Google Scholar
• Jin-Sung Park A, Kim I-K, Han S, et al. Normalization of tumor vessels by tie2 activation and ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2017;31:157–158.
   PubMed Web of Science ®Google Scholar
• Nesmith JE, Chappell JC, Cluceru JG, et al. Blood vessel anastomosis is spatially regulated by Flt1 during angiogenesis. Development. 2017;144:889–896.
   PubMed Web of Science ®Google Scholar
• Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002;285:247–256.
   PubMed Web of Science ®Google Scholar
• Filipp FV. Crosstalk between epigenetics and metabolism—yin and Yang of histone demethylases and methyltransferases in cancer. Brief Funct Genomics. 2017;16:320–325.
   PubMed Web of Science ®Google Scholar
• Judson I, Morden JP, Kilburn L, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;S1470-S2045: 30215–30213.
   Google Scholar
• Goodwin ML, Jin H, Straessler K, et al. Modeling alveolar soft part sarcomagenesis in the mouse: A Role for Lactate in the Tumor Microenvironment. Cancer Cell. 2014;26:851–862.
   PubMed Web of Science ®Google Scholar
• Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143:512–519.
   PubMed Web of Science ®Google Scholar
• Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(6):837–848.
   PubMed Web of Science ®Google Scholar
• Patwardhan PP, Musi E, Schwartz GK. Preclinical evaluation of nintedanib, a triple angiokinase inhibitor, in soft-tissue sarcoma: potential therapeutic implication for synovial sarcoma. Mol Cancer Ther. 2018;17:2329–2340.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther. 2018;364:494–503.
   PubMed Web of Science ®Google Scholar
• Ph II nintedanib vs ifosfamide in soft tissue sarcoma (ANITA), EORTC. 2018 [cited 2019 Jun 5]; NCT02808247, Available from: https://clinicaltrials.gov/ct2/show/NCT02808247
   Google Scholar
• Tang L, Yu W, Wang Y, et al. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol. 2019. doi: 10.1007/s12094-019-02090-2 [EPub ahead of print].
   Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24:5233–5238.
   PubMed Web of Science ®Google Scholar
• A phase III trial of anlotinib in metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma (APROMISS), Advenchen Laboratories LLC. 2019 [cited 2019 Jun 5]; NCT03016819, Available from: https://clinicaltrials.gov/ct2/show/NCT03016819
   Google Scholar
• Ingham M, Lee SM, Patwardhan P, et al. Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma. J Clin Oncol. 2017;35:TPS11082.
   Web of Science ®Google Scholar
• Sitravatinib in advanced liposarcoma and other soft tissue sarcomas, Mirati Therapeutics Inc. 2019 [cited 2019 Jun 5]; NCT02978859, Available from: https://clinicaltrials.gov/ct2/show/NCT02978859
   Google Scholar
• Oyama R, Takahashi M, Yoshida A, et al. Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines. Sci Rep. 2017;7:4712.
   PubMed Web of Science ®Google Scholar
• Fleuren EDG, Vlenterie M, Van Der Graaf WTA, et al. Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes. Cancer Res. 2017;77:4279–4292.
   PubMed Web of Science ®Google Scholar
• Noujaim J, Payne LS, Judson I, et al. Phosphoproteomics in translational research: a sarcoma perspective. Ann Oncol. 2016;27:787–794.
   PubMed Web of Science ®Google Scholar
• Megiorni F, McDowell HP, Camero S, et al. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. J Exp Clin Cancer Res. 2015;34:112.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Wozniak A, Kasper B, et al. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: european Organization for Research and Treatment of Cancer (EORTC) phase II trial 9010 ‘CREATE’. Ann Oncol. 2018;29:758–765.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018;6:431–441.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: european Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE.’. Ann Oncol. 2017;28:3000–3008.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Davis IJ, Argani P, et al. TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. Cancer Res. 2007;67:919–929.
   PubMed Web of Science ®Google Scholar
• Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010;70:639–645.
   PubMed Web of Science ®Google Scholar
• Jones RL, Constantinidou A, Thway K, et al. Chemotherapy in clear cell sarcoma. Med Oncol. 2011;28:859–863.
   PubMed Web of Science ®Google Scholar
• Yeung CL, Ngo VN, Grohar PJ, et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32:5429–5438.
   PubMed Web of Science ®Google Scholar
• Aslam MI, Abraham J, Mansoor A. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2014;111:6383–6388.
   PubMed Web of Science ®Google Scholar
• Michels S, Trautmann M, Sievers E, et al. SRC signalling is crucial in the growth of synovial sarcoma cells. Cancer Res. 2013;73:2518–2528.
   PubMed Web of Science ®Google Scholar
• Sievers E, Trautmann M, Kindler D, et al. SRC inhibition represents a potential therapeutic strategy in liposarcoma. Int J Cancer. 2015;137:2578–2588.
   PubMed Web of Science ®Google Scholar
• Mukaihara K, Tanabe Y, Kubota D, et al. Cabozantinib and dasatinib exert anti-tumor activity in alveolar soft part sarcoma. PloS One. 2017;12:e0185321.
   PubMed Web of Science ®Google Scholar
• Brodin BA, Wennerberg K, Lidbrink E, et al. Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Br J Cancer. 2019;120:435–443.
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123:90–97.
   PubMed Web of Science ®Google Scholar
• FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018 [cited 2019 Jul 3]; Food and Drug Administration, Available from: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0
   Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion–positive Cancers in Adults and Children. N Engl J Med. 2018;378:731–739.
   PubMed Web of Science ®Google Scholar
• Phase 1/2 Study of LOXO-195 in patients with previously treated NTRK Fusion Cancers, Loxo Oncology, Inc.. 2017 [cited 2019 Jun 21]; NCT03215511, ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03215511
   Google Scholar
• Kasper B, Sleijfer S, Litière S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 2014;25:719–724.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46:72–83.
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Huang X, Blackstein ME, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009;15:5869–5877.
   PubMed Web of Science ®Google Scholar
• Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643–2650.
   PubMed Web of Science ®Google Scholar
• Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012;7:e26331.
   PubMed Web of Science ®Google Scholar
• Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imagining. 2005;32:153–162.
   PubMed Web of Science ®Google Scholar
• Vlenterie M, Oyen WJ, Steeghs N, et al. Early metabolic response as a predictor of treatment outcome in patients with metastatic soft tissue sarcomas. Anticancer Res. 2019;39:1309–1316.
   PubMed Web of Science ®Google Scholar
• Bouchet S, Titier K, Moore N, et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol. 2013;27:690–697.
   PubMed Web of Science ®Google Scholar
• Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer. 2016;57:31–38.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497–2506.
   PubMed Web of Science ®Google Scholar
• Hornecker M, Blanchet B, Billemont B, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs. 2012;30:1991–2000.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumour activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–437.
   PubMed Web of Science ®Google Scholar
• Trnkova ZJ, Grothey A, Sobrero A, et al. Population pharmacokinetics analysis of regorafenib and its active metabolites from the phase III CORRECT study of metastatic colorectal cancer. Ann Oncol. 2013;24:iv37.
   Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727.
   PubMed Web of Science ®Google Scholar
• Garrett M, Poland B, Brennan M, et al. Population pharmacokinetic analysis of axitinib in healthy volunteers. Br J Clin Pharmacol. 2014;77:480–492.
   PubMed Web of Science ®Google Scholar
• Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174–5181.
   PubMed Web of Science ®Google Scholar
• Schmid U, Liesenfeld KH, Fleury A, et al. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemother Pharmacol. 2018;81:89–101.
   PubMed Web of Science ®Google Scholar
• Wang E, Nickens DJ, Bello A, et al. Clinical implications of the pharmacokinetics of crizotinib in populations of patients with non-small cell lung cancer. Clin Cancer Res. 2016;22:5722–5728.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692–706.
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19:705–714.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Beijnen JH, Schellens JHM, et al. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56:987–997.
   PubMed Web of Science ®Google Scholar
• Wind S, Schmid U, Freiwald M, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58:1131–1147.
   PubMed Web of Science ®Google Scholar
• Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18:5780–5787.
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist. 2012;17:1204–1212.
   PubMed Web of Science ®Google Scholar
• FDA Approved Drug Products, FDA. 2019 [cited 2019 Oct 16]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
   Google Scholar
• Lassen U, Miller WH, Hotte S. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemother Pharmacol. 2013;71:543–549.
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Tang W, McCormick A, Li J, et al. Clinical pharmacokinetics and pharmacodynamics of cediranib. Clin Pharmacokinet. 2017;56:689–702.
   PubMed Web of Science ®Google Scholar
• Zhong CC, Chen F, Yang JL, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin. 2018;39:1048–1063.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357–371.
   PubMed Web of Science ®Google Scholar
• Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909–1916.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Bins S, Mathijssen RH, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22:5738–5746.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Swart LE, Beijnen JH, et al. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol. 2017;80:1171–1178.
   PubMed Web of Science ®Google Scholar
• Lee ATJ, Pollack SM, Huang P, et al. Phase III Soft Tissue Sarcoma Trials: success or failure? Curr Treat Options Oncol. 2017;18:19.
   PubMed Web of Science ®Google Scholar
• Calvo E, Schmidinger M, Heng DYC, et al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016;50:109–117.
   PubMed Web of Science ®Google Scholar